Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HCW Biologics (HCWB) Cost of Revenue (2022 - 2025)

HCW Biologics (HCWB) has disclosed Cost of Revenue for 4 consecutive years, with $12485.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue fell 96.34% year-over-year to $12485.0, compared with a TTM value of $337620.0 through Sep 2025, down 85.71%, and an annual FY2024 reading of $1.6 million, down 29.54% over the prior year.
  • Cost of Revenue was $12485.0 for Q3 2025 at HCW Biologics, up from $5240.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.4 million in Q3 2022 and bottomed at $4052.0 in Q1 2025.
  • Average Cost of Revenue over 4 years is $536420.8, with a median of $438443.0 recorded in 2024.
  • The sharpest move saw Cost of Revenue skyrocketed 1644.34% in 2024, then tumbled 99.21% in 2025.
  • Year by year, Cost of Revenue stood at $1.1 million in 2022, then dropped by 0.17% to $1.1 million in 2023, then tumbled by 70.52% to $315843.0 in 2024, then crashed by 96.05% to $12485.0 in 2025.
  • Business Quant data shows Cost of Revenue for HCWB at $12485.0 in Q3 2025, $5240.0 in Q2 2025, and $4052.0 in Q1 2025.